<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
    "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">

<html xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <meta name="generator"
    content="HTML Tidy for FreeBSD (vers 1st April 2002), see www.w3.org" />
    <meta http-equiv="Content-Type"
    content="text/html; charset=windows-1252" />
    <base
    href="http://www.cirp.org/library/disease/HIV/cochrane2001/" />

    <title>Male circumcision for prevention of heterosexual
    acquisition of HIV in men</title>
    <meta name="robots" content="index, follow" />
    <meta name="keywords"
    content="HIV, circumcision, Cochrane, Cochrane Library, Cochrane review" />
    <meta name="description"
    content="A Cochrane Review of the literature concerning possible prevention of HIV infection by male circumcision." />

    <script type="text/javascript" language="JavaScript">
    //<![CDATA[
// bust out of a frame
<!-- hide
var caught = 0;
if (top.frames.length != 0) {
  caught++;
  if (caught != 0)
  {
    top.location=self.document.location;
  }
}
// end hide -->
    //]]>
    </script>

    <style type="text/css">
<!--
/*<![CDATA[*/
body
{
background-color: white;
}
div.corpus
{
margin-left: 10%;
margin-right: 10%;
}
h1
{
font-weight: bold; 
font-size: 10pt; 
text-transform: uppercase; 
font-family: Verdana, Arial; 
text-align: center
}
.Authors 
{
font-weight: normal; text-align: center
}
.small 
{
font-size: 8pt; font-family: Verdana, Arial; text-align: center
}
.Level2 
{
font-weight: bold
}
p 
{
margin-top: 2px; 
margin-bottom: 16px;
font-family: arial, verdana, helvetica;
font-size: 10pt;
color: navy;
}
p.url
{
color: black;
}
.trial 
{
margin: 0.2em 2em;
font-family: verdana, arial, helvetica;
font-size: 8pt;
color: navy;
}
span.yellow
{
background-color: #ff9;
}
p.navlink
{
font-size: 12pt;
font-family: "times new roman", times, serif;
text-align: center;
}
p.library
{
font-size: 13pt;
text-align: center;
font-family: "times new roman", times, serif;
font-weight: bold;
color: black;
}
span.sclibrary
{
font-size: 8.45pt;
}
/*]]>*/
-->
    </style>
  </head>

  <body bgcolor="white">
    <p class="library">T<span class="sclibrary">HE</span> C<span
    class="sclibrary">IRCUMCISION</span> R<span
    class="sclibrary">EFERENCE</span> L<span
    class="sclibrary">IBRARY</span></p>
    <hr size="1" color="black" />

    <h3>THE COCHRANE LIBRARY, 31 July 2001.</h3>
    <br />
    <br />

    <div class="corpus">
      <table summary="">
        <tbody>
          <tr>
            <td>
              <div id="comcrit" style="DISPLAY: none">
                <font face="Arial, Verdana, Helvetica" color="navy"
                size="2">CD003362</font>
              </div>

              <div>
                <h1><font face="Arial, Verdana, Helvetica"
                color="navy" size="2">Male circumcision for
                prevention of heterosexual acquisition of HIV in
                men</font></h1>

                <div style="font-weight: bold; text-align: center">
                  <font face="Arial, Verdana, Helvetica"
                  color="navy" size="2">(Protocol)</font>
                </div>
                <font face="Arial, Verdana, Helvetica" color="navy"
                size="2"><br />
                </font> 

                <div class="Authors">
                  <font face="Arial, Verdana, Helvetica"
                  color="navy" size="2">Siegfried N, Muller M,
                  Volmink J, Egger M, Low N, Weiss H, Walker S,
                  Deeks J, Williamson P</font>
                </div>
                <font face="Arial, Verdana, Helvetica" color="navy"
                size="2"><br />
                </font> 

                <p class="small"><font
                face="Arial, Verdana, Helvetica" color="navy"
                size="2">Date of most recent substantive amendment:
                3 July 2001</font></p>

                <div class="small">
                  <font face="Arial, Verdana, Helvetica"
                  color="navy" size="2">This protocol should be
                  cited as: Siegfried N, Muller M, Volmink J, Egger
                  M, Low N, Weiss H, Walker S, Deeks J, Williamson
                  P. Male circumcision for prevention of
                  heterosexual acquisition of HIV in men (Protocol
                  for a Cochrane Review). In: The Cochrane Library,
                  Issue 2, 2003. Oxford: Update Software</font>
                </div>
                <font face="Arial, Verdana, Helvetica" color="navy"
                size="2"><br />
                <br />
                <a id="BACKGROUND" name="BACKGROUND"></a></font> 

                <table summary="" cellspacing="0" cellpadding="2"
                width="100%" border="0">
                  <tbody>
                    <tr>
                      <td align="left" bgcolor="whitesmoke"><font
                      face="Verdana, Arial, Helvetica"
                      color="orchid"
                      size="2"><b>BACKGROUND</b></font></td>
                    </tr>

                    <tr>
                      <td align="middle" height="9">
                      </td>
                    </tr>
                  </tbody>
                </table>

                <p>Male circumcision is defined as the surgical
                removal of all or part of the prepuce (foreskin) of
                the penis and may be practiced as part of a
                religious ritual usually conducted shortly after
                birth, as a medical procedure related to
                infections, injury or anomalies of the foreskin, or
                as part of a traditional ritual performed as an
                initiation into manhood (<a href="#O-9">Horizons
                00</a>). For over a decade observational studies
                have pointed to an association between male
                circumcision and HIV infection in males. Most of
                these studies suggest a protective effect of male
                circumcision on HIV acquisition in men.</p>

                <p>Five reviews (<a href="#O-13">Moses 94</a>; <a
                href="#O-5">De Vincenzi 94</a>; <a
                href="#O-14">Moses 98</a>; <a href="#O-19">Van Howe
                99</a>; <a href="#O-20">Weiss 00</a>) and one
                meta-analysis (<a href="#O-20">Weiss 00</a>) of
                these observational studies have been published,
                reaching different conclusions on the association
                between circumcision and HIV infection. However,
                search strategies are not clearly described in all
                the reviews, several focused only on published
                studies and confounding was not always assessed
                adequately. The most rigorous is a systematic
                review and meta-analysis recently published by
                Weiss (<a href="#O-20">Weiss 00</a>), but this
                review was limited to published studies on HIV-1
                infection in sub-Saharan Africa. Adjusted analyses
                produced a relative risk (RR) of 0.42 (95% CI:
                0.34-0.54) for all studies combined (N=15) with a
                RR of 0.55 (95% CI: 0.42 - 0.72) for
                population-based cross-sectional studies (N=5) and
                a RR of 0.24 (95% CI: 0.18 - 0.31) for
                cross-sectional studies of high-risk groups (N=4).
                The authors conclude that there is compelling
                evidence that male circumcision is associated with
                a reduced risk of HIV infection in sub-Saharan
                Africa despite warning that residual confounding
                may exist in some studies due to behavioural or
                biological factors that are unknown or
                unmeasured.</p>

                <p>Known sources of confounding identified by all
                the above reviews include sexual behaviour, penile
                hygiene and religion. Circumcision itself may be a
                proxy measure of the knowledge and behaviour learnt
                during the process of initiation during which time
                young men are taught about traditional sexual
                practices, including monogamy, and penile hygiene.
                A potential confounder that has not been measured
                in any study to date to our knowledge is the use of
                vaginal drying agents in female partners of the
                men. This practice is reportedly common in parts of
                Africa (<a href="#O-1">Brown 93</a>; <a
                href="#O-11">Kun 98</a>; <a href="#O-16">Runganga
                95</a>) and may result in increased vaginal
                abrasions and micro-lacerations, possibly
                facilitating HIV transmission in both directions.
                Viral load is increasingly considered to be a
                crucial factor in HIV transmission (<a
                href="#O-15">Quinn 00</a>) and may be both an
                important confounder and an effect modifier.
                Misclassification of exposure is also an important
                source of bias given that some studies classify
                circumcision status by self-report rather than
                direct observation.</p>

                <p>Biological theories to support the protective
                effect of circumcision on HIV exist. Researchers
                have noted that the inner aspect of the foreskin is
                well-supplied with Langerhans cells (<a
                href="#O-18">Szabo 00</a>) and that in vitro, HIV-1
                demonstrates a specific tropism (attraction) for
                these cells (<a href="#O-17">Soto-Ramirez 96</a>),
                in particular the CD4 receptors (<a
                href="#O-10">Hussain 95</a>). CD4 and other HIV
                co-receptors have been shown to facilitate HIV
                entry into host cells, although this has yet to be
                demonstrated specifically for preputial Langerhans
                cells. According to this theory, circumcision would
                remove the potential entry site for HIV. <span
                class="yellow">However, not all Langerhans cells
                are removed during circumcision as even after the
                procedure, there is residual penile mucosa of the
                glans and there are also Langerhans cells in the
                penile shaft (<a href="#O-4">Cold 99</a>). In
                direct contradiction to the above theory, the inner
                prepuce contains apocrine glands which secrete
                lysozyme (<a href="#O-6">Fleiss 98</a>). Lysozyme
                reportedly kills HIV-1 <i>in vitro</i> (<a
                href="#O-12">Lee-Huang 99</a>), suggesting a
                protective effect of the foreskin. As the study of
                the immunological function of the prepuce is not
                well-developed (<a href="#O-4">Cold 99</a>),
                caution must be observed when assuming <i>in
                vitro</i> viral behaviour is equivalent <i>in
                vivo</i>.</span></p>

                <p>The presence of a sexually transmitted infection
                (STI) enhances HIV infection and susceptibility (<a
                href="#O-3">Cohen 98</a>; <a href="#O-8">Grosskurth
                95</a>; <a href="#O-7">Fleming 99</a>). The role
                circumcision plays in the transmission of STIs is
                less certain, although it has been reported that
                male circumcision is associated with a reduced risk
                of genital ulcer disease, particularly chancroid
                and syphilis (<a href="#O-14">Moses 98</a>). It
                would therefore be valuable to examine the
                relationship between circumcision and STIs. Should
                this relationship prove to be temporal, it seems
                likely that circumcision may protect against HIV
                infection indirectly via decreased STI
                transmission.</p>

                <p><span class="yellow">Circumcision practices are
                largely culturally determined and as a result there
                are strong beliefs and opinions surrounding its
                practice. It is important to acknowledge that
                researchers' personal biases and the dominant
                circumcision practices of their respective
                countries may influence their interpretation of
                findings.</span></p>

                <p>Given the enormous mortality and morbidity
                associated with HIV/AIDS, it seems reasonable to
                fully explore potential prevention measures,
                including male circumcision. However, promoting or
                instituting mass circumcision may have profound
                cultural and social implications and represents a
                formidable public health challenge (<a
                href="#O-2">Cohen 00</a>). <span class="yellow">Of
                particular concern is the potential negative impact
                introduction of circumcision may have on current
                health promotion endeavours to promote sexual
                behavioural change. This may include promulgation
                of the belief that circumcision completely protects
                against HIV transmission, resulting in a lack of
                condom use.</span> The following <a
                href="/library/disease/HIV/cochrane2003/">systematic
                review</a> seeks to inform this debate by
                presenting the evidence from both published and
                unpublished studies from around the world which
                examine the association between circumcision and
                HIV-1 and HIV-2 infection.</p>
                <font face="Arial, Verdana, Helvetica" color="navy"
                size="2"><br />
                <a id="OBJECTIVES" name="OBJECTIVES"></a></font> 

                <table summary="" cellspacing="0" cellpadding="2"
                width="100%" border="0">
                  <tbody>
                    <tr>
                      <td align="left" bgcolor="whitesmoke"><font
                      face="Verdana, Arial, Helvetica"
                      color="orchid"
                      size="2"><b>OBJECTIVES</b></font></td>
                    </tr>

                    <tr>
                      <td align="middle" height="9">
                      </td>
                    </tr>
                  </tbody>
                </table>

                <p>1) To examine the association between male
                circumcision and acquisition of HIV-1 and HIV-2 by
                men through heterosexual intercourse.<br />
                2) To examine the feasibility and value of
                performing individual person data (IPD)
                meta-analysis.</p>
                <font face="Arial, Verdana, Helvetica" color="navy"
                size="2"><br />
                <a id="CRITERIA" name="CRITERIA"></a></font> 

                <table summary="" cellspacing="0" cellpadding="2"
                width="100%" border="0">
                  <tbody>
                    <tr>
                      <td align="left" bgcolor="whitesmoke"><font
                      face="Verdana, Arial, Helvetica"
                      color="orchid" size="2"><b>CRITERIA FOR
                      CONSIDERING STUDIES FOR THIS
                      REVIEW</b></font></td>
                    </tr>

                    <tr>
                      <td align="middle" height="9">
                      </td>
                    </tr>
                  </tbody>
                </table>

                <div class="Level2">
                  <font face="Arial, Verdana, Helvetica"
                  color="navy" size="2">Types of studies</font>
                </div>

                <p>Randomised or quasi-randomized controlled
                trials. If insufficient data are available from
                randomised controlled trials to draw any meaningful
                conclusions, data from observational studies (e.g.
                cohort, case-control and cross-sectional studies)
                will be considered for inclusion in this review.
                Studies performed in general or specific
                populations and in hospitals or clinics will be
                included. Studies performed in any country and
                published in any language will be included. Studies
                with historical controls and ecological studies
                will be excluded.</p>

                <div class="Level2">
                  <font face="Arial, Verdana, Helvetica"
                  color="navy" size="2">Types of
                  participants</font>
                </div>

                <p>Heterosexual men included in studies assessing
                the association between circumcision and HIV-1 and
                HIV-2. Men are defined as males 12 years or
                older.</p>

                <div class="Level2">
                  <font face="Arial, Verdana, Helvetica"
                  color="navy" size="2">Types of
                  intervention</font>
                </div>

                <p>Male circumcision is defined as removal of the
                foreskin of the penis either via surgical technique
                or via cultural practices which involve cutting off
                the foreskin. Circumcision status can be determined
                by self- or partner-report or by direct
                observation.</p>

                <div class="Level2">
                  <font face="Arial, Verdana, Helvetica"
                  color="navy" size="2">Types of outcome
                  measures</font>
                </div>

                <p>The outcome measures are:</p>

                <p>HIV-1 or HIV-2 infection in men</p>

                <p>Any adverse events associated with circumcision
                will be recorded if reported in the trials.</p>
                <font face="Arial, Verdana, Helvetica" color="navy"
                size="2"><br />
                <a id="SEARCH_STRATEGY"
                name="SEARCH_STRATEGY"></a></font> 

                <table summary="" cellspacing="0" cellpadding="2"
                width="100%" border="0">
                  <tbody>
                    <tr>
                      <td align="left" bgcolor="whitesmoke"><font
                      face="Verdana, Arial, Helvetica"
                      color="orchid" size="2"><b>SEARCH STRATEGY
                      FOR IDENTIFICATION OF STUDIES</b></font></td>
                    </tr>

                    <tr>
                      <td align="middle" height="9">
                      </td>
                    </tr>
                  </tbody>
                </table>

                <p>See: HIV/AIDS Collaborative Review Group search
                strategy</p>

                <p>Electronic searches will be undertaken using the
                following databases: MEDLINE, Embase, AIDSLINE,
                CINAHL, Scisearch, the Cochrane Controlled Trials
                Register, Database of Abstracts of Reviews of
                Effectiveness (DARE), the Cochrane HIV/AIDS and the
                Cochrane STD registers of studies. Hand searches of
                the reference lists of all pertinent reviews and
                studies found will also be undertaken, as well as
                abstracts from relevant conferences. Agencies,
                organizations and academic centers, as well as
                experts in the field of HIV prevention will be
                contacted to locate any further studies or relevant
                conference proceedings that may not be included in
                the databases and to ensure that unpublished
                studies are included.</p>

                <p>The search strategy will be iterative.</p>
                <font face="Arial, Verdana, Helvetica" color="navy"
                size="2"><br />
                <a id="METHODS" name="METHODS"></a></font> 

                <table summary="" cellspacing="0" cellpadding="2"
                width="100%" border="0">
                  <tbody>
                    <tr>
                      <td align="left" bgcolor="whitesmoke"><font
                      face="Verdana, Arial, Helvetica"
                      color="orchid" size="2"><b>METHODS OF THE
                      REVIEW</b></font></td>
                    </tr>

                    <tr>
                      <td align="middle" height="9">
                      </td>
                    </tr>
                  </tbody>
                </table>

                <p>The search for trials will be performed with the
                assistance of the Cochrane HIV/AIDS Group. The
                selection for potentially relevant studies will be
                undertaken by NS and MM. The titles, abstracts and
                descriptor terms of all downloaded material from
                the electronic searches will be read and irrelevant
                reports discarded to create a pool of potentially
                eligible studies. All citations identified will
                then be independently inspected by NS and MM to
                establish relevance of the article and whether or
                not the full article should be acquired. If there
                is uncertainty, the full article will be
                obtained.</p>

                <p>1. Selection of studies<br />
                 NS and MM will independently apply the inclusion
                criteria. Differences will be resolved by
                discussions with a third reviewer, JV. Studies will
                be reviewed for relevance based on study design,
                types of participants, exposures and outcome
                measures. Finally, where resolution is not possible
                because further information is necessary, the study
                will be allocated to the list of those awaiting
                assessment. Attempts will then be made to contact
                authors to provide further clarification of
                data.</p>

                <p>2. Data extraction<br />
                 Data will be extracted independently by NS and MM
                using a standardised data extraction form. The
                following characteristics will be extracted from
                each included study:</p>

                <p>Administrative details:<br />
                 Identification; author(s); published or
                unpublished; year of publication; number of studies
                included in paper; year in which study was
                conducted; details of other relevant papers
                cited.</p>

                <p><font face="Arial, Verdana, Helvetica"
                color="navy" size="2">Details of study:<br />
                 Study design; type, duration and completeness of
                follow-up in the case of cohort studies; country
                and location of the study; setting in which the
                study was performed (e.g. urban or rural;
                population or hospital/clinic based); background
                HIV prevalence of the selected study sample
                (high-risk or low-risk); method(s) of recruitment;
                number of participants</font></p>

                <p>Characteristics of participants:<br />
                 Age; religion; socio-economic status; dominant
                cultural practices regarding circumcision; number
                of sexual partners; condom use; other identified
                risk factors (e.g. presence of sexually transmitted
                infections; use of vaginal drying agents in female
                partner)</p>

                <p>Details of intervention:<br />
                 Circumcision based on self- or partner-report or
                direct observation; age at circumcision;
                circumcision procedure used (surgical procedure or
                traditional); reason for circumcision (traditional
                beliefs or medical treatment)</p>

                <p>Details of outcomes:<br />
                 HIV infection (incidence and prevalence); number
                of HIV positive men in the circumcised and
                uncircumcised groups (n/N) (except for case-control
                studies, where number of men circumcised in the
                case and control groups will be recorded); types of
                tests used to determine HIV status; method of
                surveillance of adverse effects associated with
                circumcision; number of men with specific adverse
                effects associated with circumcision (n/N).</p>

                <p><br />
                 3. Quality assessment<br />
                 Quality assessment will be done using a
                standardised quality assessment form.</p>

                <p>Randomised Controlled Trials:<br />
                 The methodological quality of the included trials
                will be evaluated independently by NS and MM in
                terms of method of randomisation, adequacy of
                allocation concealment, blinding,
                intention-to-treat and loss-to-follow-up.</p>

                <p>Observational Studies:<br />
                 The methodological quality of the included cohort,
                case-control and cross-sectional studies will be
                evaluated independently by NS and MM. One further
                reviewer JD will check the use of quality
                assessment. In all types of studies, particular
                emphasis will be placed on the method of selection
                of the sample (criteria specific to the study
                design), method of ascertainment of circumcision
                status, and method of ascertainment of HIV status.
                In cohort studies, quality assessment will include
                the type, length and completeness of follow-up and
                in case-control studies, case definition and
                control selection will be included.</p>

                <p>Reviewers will not be blinded to the names of
                the authors, institutions, journal of publication
                or results of the studies.</p>

                <p><br />
                 4. Data synthesis<br />
                 Incomplete data:<br />
                 If data are incomplete, attempts will be made to
                contact the authors for clarification of important
                information.<br />
                <br />
                 Outcome measures:<br />
                 All outcomes included in this review will be
                binary. Measures of association for each study will
                be expressed as crude and adjusted odds ratios
                together with their 95% confidence intervals. Odds
                ratio will be used because they are the only valid
                estimator from case-control studies, and from
                adjusted analyses obtained from logistic
                regression. To assist interpretation the overall
                results will be translated into measures of
                absolute benefit (attributable risk percent) for
                both population-based and high-risk groups.</p>

                <p><font face="Arial, Verdana, Helvetica"
                color="navy" size="2">5. Sub-group analysis,
                investigation of heterogeneity and sensitivity
                analysis<br />
                 Meta-analysis will be stratified according to
                study design (RCT versus cohort studies versus
                case-control versus cross-sectional studies).
                Within each study design strata we will further
                stratify for population studies versus studies in
                groups perceived to be at high risk of
                HIV.</font></p>

                <p>Where possible meta-analysis will be conducted
                combining odds ratios using a random effects
                (DerSimonian and Laird) model as between study
                heterogeneity is anticipated. Heterogeneity will be
                tested by REVMAN software using the Chi square test
                for heterogeneity. Between-study heterogeneity (p
                &lt;0.1) will be explored by subgroup analysis and
                meta-regression depending on the data available.
                The following study factors will be examined:</p>

                <p>- Circumcision: studies which assess status by
                self-report versus direct observation; medical
                procedure versus traditional procedure<br />
                 - Background prevalence of HIV (low or high) in
                the general population of the study country or
                study region<br />
                 - HIV type: HIV 1 or HIV 2<br />
                <br />
                 The effect of continuous variables such as number
                of sexual partners in a specified time will be
                further explored using random effects
                meta-regression (STATA) if data allow. In cases
                where a meta-analysis is not possible and/or
                appropriate, narrative data synthesis will be
                provided.</p>

                <p>We will conduct sensitivity analysis based on
                study quality using meta-regression if appropriate.
                The following effects will also be investigated
                using sensitivity analysis:</p>

                <p>- Adjusted and unadjusted analyses<br />
                 - Published and unpublished studies</p>
                <font face="Arial, Verdana, Helvetica" color="navy"
                size="2"><br />
                <a id="CONFLICT" name="CONFLICT"></a></font> 

                <table summary="" cellspacing="0" cellpadding="2"
                width="100%" border="0">
                  <tbody>
                    <tr>
                      <td align="left" bgcolor="whitesmoke"><font
                      face="Verdana, Arial, Helvetica"
                      color="orchid" size="2"><b>POTENTIAL CONFLICT
                      OF INTEREST</b></font></td>
                    </tr>

                    <tr>
                      <td align="middle" height="9">
                      </td>
                    </tr>
                  </tbody>
                </table>

                <p>None known.</p>
                <font face="Arial, Verdana, Helvetica" color="navy"
                size="2"><br />
                <a id="REFERENCES" name="REFERENCES"></a></font> 

                <table summary="" cellspacing="0" cellpadding="2"
                width="100%" border="0">
                  <tbody>
                    <tr>
                      <td align="left" bgcolor="whitesmoke"><font
                      face="Verdana, Arial, Helvetica"
                      color="orchid"
                      size="2"><b>REFERENCES</b></font></td>
                    </tr>

                    <tr>
                      <td align="middle" height="9">
                      </td>
                    </tr>
                  </tbody>
                </table>

                <div class="Level2">
                  <font face="Arial, Verdana, Helvetica"
                  color="navy" size="2"><font
                  face="Verdana, Arial, Helvetica" color="navy"
                  size="1">Additional references</font></font>
                </div>
                <font face="Arial, Verdana, Helvetica" color="navy"
                size="2"><font face="Verdana, Arial, Helvetica"
                color="navy" size="1"><br />
                <a id="O-1" name="O-1"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Brown 93</font></a></font></font> 

                <p class="trial">Brown J.E., Ayowa O.B., Brown R.C.
                <a href="/library/disease/HIV/brown1/">Dry and
                tight - sexual practices and potential AIDS risk in
                Zaire</a>. Social Science and Medicine
                1993;37:989-994.<br />
                <br />
                </p>
                <a id="O-2" name="O-2"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Cohen 00</font></a> 

                <p class="trial">Cohen M.S. <a
                href="http://content.nejm.org/cgi/content/extract/342/13/970"
                 target="_blank">Preventing sexual transmission of
                HIV - new ideas from sub-Saharan Africa</a> The New
                England Journal of Medicine 2000;342:970 -
                972.<br />
                <br />
                </p>
                <a id="O-3" name="O-3"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Cohen 98</font></a> 

                <p class="trial">Cohen M.S. Sexually transmitted
                diseases enhance HIV transmission: no longer a
                hypothesis. The Lancet 1998;351 Suppl:S5 -
                S7.<br />
                <br />
                </p>
                <a id="O-4" name="O-4"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Cold 99</font></a> 

                <p class="trial">Cold C.J., Taylor J.R. <a
                href="/library/anatomy/cold-taylor/">The
                prepuce</a>. British Journal of Urology
                1999;83:34-44.<br />
                <br />
                </p>
                <a id="O-5" name="O-5"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">De Vincenzi 94</font></a> 

                <p class="trial">De Vincenzi I.D., Mertens T. <a
                href="/library/disease/HIV/vincenzi/">Male
                circumcision: a role in HIV prevention?</a>. AIDS
                1994;8:153-160.<br />
                <br />
                </p>
                <a id="O-6" name="O-6"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Fleiss 98</font></a> 

                <p class="trial">Fleiss P.M., Hodges F.M., Van Howe
                R.S. <a
                href="/library/disease/STD/fleiss3/">Immunological
                function of the human prepuce</a>. Sexually
                Transmitted Infections 1998;74:364-367.<br />
                <br />
                </p>
                <a id="O-7" name="O-7"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Fleming 99</font></a> 

                <p class="trial">D.T. Fleming, J.D. Wasserheit. <a
                href="/library/disease/HIV/fleming1/">From
                epidemiological synergy to public health policy and
                practice: the contribution of other sexually
                transmitted diseases to sexual transmission of HIV
                infection</a>. Sexually Transmitted Infections
                1999;75:3-17.<br />
                <br />
                </p>
                <a id="O-8" name="O-8"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Grosskurth 95</font></a> 

                <p class="trial">Grosskurth H., Mosha F., Todd J.,
                Mwijarubi E., Klokke E., Senkoro K., Mayaud P.,
                Changalucha J., Nicoll A., ka-Gina G., Newell J.,
                Mugeye K., Mabey D., Hayes R. <a
                href="/library/disease/HIV/grosskurth2/">Impact of
                improved treatment of sexually transmitted diseases
                on HIV infections in rural Tanzania: randomised
                controlled trial</a>. The Lancet
                1995;346:530-536.<br />
                <br />
                </p>
                <a id="O-9" name="O-9"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Horizons 00</font></a> 

                <p class="trial">Horizons. Report: Male
                circumcision and HIV prevention: Directions for
                future research.. Washington DC: Office of Health
                and Nutrition, Global Bureau, U.S. Agency for
                International Development. 2000.<br />
                <br />
                </p>
                <a id="O-10" name="O-10"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Hussain 95</font></a> 

                <p class="trial">Hussain L. A., Lehner T.
                Comparative investigation of Langerhans' cells and
                potential receptors for HIV in oral, gentourinary
                and rectal epithelia. Immunology
                1995;85:465-484.<br />
                <br />
                </p>
                <a id="O-11" name="O-11"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Kun 98</font></a> 

                <p class="trial">Kun K.E. <a
                href="/library/disease/HIV/kun1/">Vaginal drying
                agents and HIV transmission</a>. Family Planning
                Perspectives 1998;24:93-94.<br />
                <br />
                </p>
                <a id="O-12" name="O-12"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Lee-Huang 99</font></a> 

                <p class="trial">Lee-Huang S., Huang P.L., Sun Y.,
                Kung H.F., Blithe D.L., Chen H.C. <a
                href="http://www.cirp.org/library/disease/HIV/lee-huang/">
                Lysozyme and RNases as anti-HIV components in
                Beta-core preparations of human chorionic
                gonadotropin</a>. Proceedings of the National
                Academy of Science (USA). 1999;96:2678-2681.<br />
                <br />
                </p>
                <a id="O-13" name="O-13"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Moses 94</font></a> 

                <p class="trial">Moses S., Plummer F.A., Bradley
                J.E., Ndiya-Achola J.O., Nagelkerke N.J.D., Ronald
                A.R. [<a href="/library/disease/HIV/moses/">The
                association between lack of male circumcision and
                risk for HIV infection: a review of the
                epidemiological data</a>]. Sexually Transmitted
                Diseases 1994;21:201-210.<br />
                <br />
                </p>
                <a id="O-14" name="O-14"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Moses 98</font></a> 

                <p class="trial">Moses S., Bailey R.C., Donald A.R.
                Male circumcision: assessment of health benefits
                and risks. Sexually Transmitted Infections
                1998;74:368-373.<br />
                <br />
                </p>
                <a id="O-15" name="O-15"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Quinn 00</font></a> 

                <p class="trial">Quinn T.C., Wawer M.J., Sewankambo
                N., Serwadda D., Li C., Wabwoire-Mangen F., Meehan
                M.O., Lutalo T., Gray R.H. <a
                href="http://content.nejm.org/cgi/content/abstract/342/13/921"
                 target="_blank">Viral load and heterosexual
                transmission of human immunodeficiency virus type
                1</a>. The New England Journal of Medicine
                2000;342:921-929.<br />
                <br />
                </p>
                <a id="O-16" name="O-16"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Runganga 95</font></a> 

                <p class="trial">Runganga O.A., Kasule J. <a
                href="/library/disease/HIV/runganga2/">The vaginal
                use of herbs/substances: an HIV transmission
                facilitatory factor?</a>. AIDS CARE
                1995;7:639-645.<br />
                <br />
                </p>
                <a id="O-17" name="O-17"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Soto-Ramirez 96</font></a> 

                <p class="trial">Soto-Ramirez L. E., Renjifo B.,
                McLane M. F., Marlink R., O'Hara, C., Sutthent, R.,
                Wasi, C., Vithayasi, P., Vithayasai, V.,
                Apichartpiyakul, C., Auewarakul, P., Cruz, V. P.,
                Chui, D.-S., Osathanondh, R., Mayer, K., Lee,
                T.-H., Essex, M. HIV-1 Langerhans' cell tropism
                with heterosexual transmission of HIV. Science
                1996;271:1291-1293.<br />
                <br />
                </p>
                <a id="O-18" name="O-18"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Szabo 00</font></a> 

                <p class="trial">Szabo R., Short R.V. How does male
                circumcision protect against HIV infection?.
                British Medical Journal 2000;320:1592-1594.<br />
                <br />
                </p>
                <a id="O-19" name="O-19"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Van Howe 99</font></a> 

                <p class="trial">R.S. Van Howe. <a
                href="/library/disease/HIV/vanhowe4/">Circumcision
                and HIV infection: review of the literature and
                meta-analysis</a>. International Journal of STD and
                AIDS 1999;10:8-16.<br />
                <br />
                </p>
                <a id="O-20" name="O-20"><font
                face="Verdana, Arial, Helvetica" color="darkviolet"
                size="1">Weiss 00</font></a> 

                <p class="trial">Weiss H.A., Quigley M.A., Hayes R.
                Male circumcision and risk of HIV infection in
                sub-Saharan Africa: a systematic review and
                meta-analysis. AIDS 2000;14:2361-2370.<br />
                <br />
                </p>
                <br />
                 <a id="COVER" name="COVER"></a> 

                <table cellspacing="0" cellpadding="2" width="90%"
                border="0" summary="cover sheet">
                  <tbody>
                    <tr>
                      <td align="left" bgcolor="whitesmoke"><font
                      face="Verdana, Arial, Helvetica"
                      color="orchid" size="2"><b>COVER
                      SHEET</b></font></td>
                    </tr>

                    <tr>
                      <td align="middle" height="9">
                      </td>
                    </tr>
                  </tbody>
                </table>

                <div class="cover">
                  <center>
                    <table summary="" cellspacing="0"
                    cellpadding="1" width="90%" border="0">
                      <tbody>
                        <tr>
                          <td bgcolor="plum">
                            <table summary="" cellspacing="0"
                            cellpadding="12" width="100%"
                            bgcolor="#F5F5F5" border="0">
                              <tbody>
                                <tr valign="top">
                                  <td><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy"
                                  size="2">Title</font></td>

                                  <td>
                                    <p><font
                                    face="Arial, Verdana, Helvetica"
                                    color="navy" size="2"><b>Male
                                    circumcision for prevention of
                                    heterosexual acquisition of HIV
                                    in men</b></font></p>
                                  </td>
                                </tr>

                                <tr valign="top">
                                  <td><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy"
                                  size="2">Reviewer(s)</font></td>

                                  <td>
                                    <p><font
                                    face="Arial, Verdana, Helvetica"
                                     color="navy"
                                    size="2"><b>Siegfried N, Muller
                                    M, Volmink J, Egger M, Low N,
                                    Weiss H, Walker S, Deeks J,
                                    Williamson P</b></font></p>
                                  </td>
                                </tr>

                                <tr valign="top">
                                  <td><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy"
                                  size="2">Contribution of
                                  reviewer(s)</font></td>

                                  <td valign="center"><font
                                  face="Arial, Verdana, Helvetica"
                                  color="red" size="2">Information
                                  not supplied by
                                  reviewer</font></td>
                                </tr>

                                <tr valign="top">
                                  <td><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy" size="2">Issue
                                  protocol first
                                  published</font></td>

                                  <td valign="center"><font
                                  face="Arial, Verdana, Helvetica"
                                  color="red" size="2">Information
                                  not available</font></td>
                                </tr>

                                <tr valign="top">
                                  <td><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy" size="2">Date of
                                  most recent amendment</font></td>

                                  <td valign="center"><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy" size="2">31 July
                                  2001</font></td>
                                </tr>

                                <tr valign="top">
                                  <td><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy" size="2">Date of
                                  most recent SUBSTANTIVE
                                  amendment</font></td>

                                  <td valign="center"><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy" size="2">3 July
                                  2001</font></td>
                                </tr>

                                <tr valign="top">
                                  <td><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy" size="2">Most recent
                                  changes</font></td>

                                  <td><font
                                  face="Arial, Verdana, Helvetica"
                                  color="red" size="2">Information
                                  not supplied by
                                  reviewer</font></td>
                                </tr>

                                <tr valign="top">
                                  <td><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy" size="2">Review
                                  expected to be published
                                  in</font></td>

                                  <td valign="center"><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy" size="2">Issue 2,
                                  2003</font></td>
                                </tr>

                                <tr valign="top">
                                  <td><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy" size="2">Contact
                                  address</font></td>

                                  <td>
                                    <div class="name">
                                      <font
                                      face="Arial, Verdana, Helvetica"
                                      color="navy" size="2">Dr
                                      Nandi Siegfried</font>
                                    </div>

                                    <div class="line">
                                      <font
                                      face="Arial, Verdana, Helvetica"
                                      color="navy"
                                      size="2">Specialist Scientist
                                      and Acting Director<br />
                                      South African Cochrane
                                      Centre; Medical Research
                                      Council<br />
                                      PO Box 19070<br />
                                      </font>
                                    </div>

                                    <div class="city">
                                      <font
                                      face="Arial, Verdana, Helvetica"
                                      color="navy"
                                      size="2">Tygerberg</font>
                                    </div>

                                    <div>
                                      <font
                                      face="Arial, Verdana, Helvetica"
                                      color="navy"
                                      size="2">7505</font>
                                    </div>

                                    <div>
                                      <font
                                      face="Arial, Verdana, Helvetica"
                                      color="navy" size="2">SOUTH
                                      AFRICA</font>
                                    </div>

                                    <div class="comms">
                                      <div>
                                        <font
                                        face="Arial, Verdana, Helvetica"
                                        color="navy" size="2">tel:
                                        +27 21 938 0836</font>
                                      </div>

                                      <div>
                                        <a
                                        href="mailto:Nsiegfri@mrc.ac.za">
                                        <font
                                        face="Arial, Verdana, Helvetica"
                                        color="navy"
                                        size="2">Nsiegfri@mrc.ac.za</font></a>
                                      </div>

                                      <div>
                                        <font
                                        face="Arial, Verdana, Helvetica"
                                        color="navy" size="2">fax:
                                        +27 21 938 0804</font>
                                      </div>
                                    </div>
                                  </td>
                                </tr>

                                <tr valign="top">
                                  <td><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy" size="2">Cochrane
                                  Library number</font></td>

                                  <td><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy"
                                  size="2">CD003362</font></td>
                                </tr>

                                <tr valign="top">
                                  <td><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy" size="2">Editorial
                                  group</font></td>

                                  <td><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy" size="2">Cochrane
                                  HIV/AIDS Group</font></td>
                                </tr>

                                <tr valign="top">
                                  <td><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy" size="2">Editorial
                                  group code</font></td>

                                  <td><font
                                  face="Arial, Verdana, Helvetica"
                                  color="navy"
                                  size="2">HM-HIV</font></td>
                                </tr>
                              </tbody>
                            </table>
                          </td>
                        </tr>
                      </tbody>
                    </table>
                  </center>
                </div>
                <br />
                <br />
                <a id="SUPPORT" name="SUPPORT"></a> 

                <table summary="" cellspacing="0" cellpadding="2"
                width="100%" border="0">
                  <tbody>
                    <tr>
                      <td align="left" bgcolor="whitesmoke"><font
                      face="Verdana, Arial, Helvetica"
                      color="orchid" size="2"><b>SOURCES OF
                      SUPPORT</b></font></td>
                    </tr>

                    <tr>
                      <td align="middle" height="9">
                      </td>
                    </tr>
                  </tbody>
                </table>

                <div class="Level2">
                  External sources of support
                </div>

                <ul>
                  <li>HRP-UNDP/UNFPA/WHO/World Bank Special
                  Programme of Research, Development and Research
                  Training in Human Reproduction, Geneva
                  SWITZERLAND</li>

                  <li>Liverpool School of Tropical Medicine UK</li>

                  <li>Effective Health Care Alliance UK</li>
                </ul>

                <div class="Level2">
                  Internal sources of support
                </div>

                <ul>
                  <li><a href="http://www.mrc.ac.za/"
                  target="_blank">Medical Research Council</a>
                  SOUTH AFRICA</li>
                </ul>
                <br />
                 <a id="TABLES" name="TABLES"></a> 

                <table summary="" cellspacing="0" cellpadding="2"
                width="100%" border="0">
                  <tbody>
                    <tr>
                      <td align="left" bgcolor="whitesmoke"><font
                      face="Verdana, Arial, Helvetica"
                      color="orchid" size="2"><b>ADDITIONAL
                      TABLES</b></font></td>
                    </tr>

                    <tr>
                      <td align="middle" height="9">
                      </td>
                    </tr>
                  </tbody>
                </table>

                <p>Additional tables are not available for this
                protocol</p>
              </div>
            </td>
          </tr>
        </tbody>
      </table>
    </div>
    <hr />

    Citation: 
    <ul>
      <li>Siegfried N, Muller M, Volmink J, Egger M, Low N, Weiss
      H, Walker S, Deeks J, Williamson P. Male circumcision for
      prevention of heterosexual acquisition of HIV in men
      (Protocol for a Cochrane Review). In: <i>The Cochrane
      Library</i>, Issue 2, 2003.</li>
    </ul>
    <hr />
    <small>(File revised 9 December 2006)</small> 

    <center>
      <p class="navlink"><a href="/library/">Return to CIRP
      Library</a></p>
    </center>

    <p class="url">
    <tt>http://www.cirp.org/library/disease/HIV/cochane2001/</tt></p>
  </body>
</html>
